Janssen Pharmaceuticals

Addex and Perceptive Launch Neurosterix with $63 Million to Accelerate Development of Allosteric Modulator Therapeutics for Neurological Disorders

Retrieved on: 
Wednesday, April 3, 2024
Discovery, Epilepsy, GABAB, Senior, Glutamic acid, Dyskinesia, Glutamate (neurotransmitter), Drug discovery, Partnership, TBI, SIX, Chronic cough, NAM, CHF5, Therapy, DSM-IV codes, Janssen, Safety, ADX71149, Allosteric regulation, Janssen Pharmaceuticals, Dipraglurant, Research fellow, PAM, Pharmaceutical industry

With initial funding of $63 million from Perceptive Xontogeny Venture Fund II, with participation from Perceptive Life Sciences Fund and Acorn Bioventures, Neurosterix will acquire a portfolio of preclinical assets and the allosteric modulator drug discovery technology platform from Addex and accelerate their development.

Key Points: 
  • With initial funding of $63 million from Perceptive Xontogeny Venture Fund II, with participation from Perceptive Life Sciences Fund and Acorn Bioventures, Neurosterix will acquire a portfolio of preclinical assets and the allosteric modulator drug discovery technology platform from Addex and accelerate their development.
  • In return, Addex will receive CHF5 million and a 20% equity interest in Neurosterix.
  • “The launch of Neurosterix in partnership with Perceptive is an important validation of the Addex allosteric modulator drug discovery technology platform and provides the resources to accelerate development of important preclinical assets, including the M4 PAM and mGlu7 negative allosteric modulator (NAM) programs, into the clinic,” said Tim Dyer, CEO of Addex.
  • To guide the launch of Neurosterix, Tim Dyer, in addition to his role at Addex, will assume the role of CEO of Neurosterix.

AstriVax Rounds Out Executive Team with Chief Business Officer (CBO) Dr. Gregory Fanning

Retrieved on: 
Tuesday, March 19, 2024
CD4, CDO, CD8, CBO, Hepatitis B, Disease, Janssen Pharmaceuticals, Death, Vaccine

His initial focus will be on the company’s candidate vaccine to treat chronic Hepatitis B and shape the future AstriVax vaccine pipeline.

Key Points: 
  • His initial focus will be on the company’s candidate vaccine to treat chronic Hepatitis B and shape the future AstriVax vaccine pipeline.
  • Leuven, Belgium, March 19, 2024 – AstriVax is pleased to welcome Dr. Gregory Fanning as its Chief Business Officer.
  • Dr. Fanning further strengthens the company’s top-notch leadership team, joining CEO and co-founder Dr. Hanne Callewaert, CTO Dr. Wilfried Dalemans, CDO Dr. Mathieu Peeters, and CFO Barbara Freitag.
  • The cure for this disease is likely to come from combining the AstriVax approach with that of several other companies.

AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update

Retrieved on: 
Thursday, March 14, 2024
University of Geneva, Diagnosis, Target, Down syndrome, MSA, Disease, ALS, PD, Safety, Multiple system atrophy, Patient, PET, Research, Geneva University Hospitals, Amyloid beta, MJFF, ABATE, Smith, University, KOL, Doctor of Philosophy, MD, TAR, IND, Medicine, AC, University of Luxembourg, Cognition, DS, Johnson & Johnson, Janssen, Sahlgrenska University Hospital, CHF, Injection, DSMB, University of Gothenburg, Food, RETAIN, Janssen Pharmaceuticals, Nature Communications, Pharmaceutical industry

Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: “We made significant progress in 2023 advancing our three innovative active immunotherapy programs in Phase 2 clinical trials in Alzheimer’s and Parkinson’s diseases.

Key Points: 
  • Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: “We made significant progress in 2023 advancing our three innovative active immunotherapy programs in Phase 2 clinical trials in Alzheimer’s and Parkinson’s diseases.
  • Six-month Abeta positron emission tomography (PET) imaging results are expected in Q2 2024, and 12-month Abeta-PET data are expected in H2 2024.
  • Comm., 2023) showed that AC Immune’s wholly-owned a-syn-PET tracer ACI-12589 can detect a-syn pathology in multiple system atrophy (MSA) and differentiate MSA from other a-synucleinopathies.
  • PI-2620 was discovered and developed using the Morphomer® platform as part of a research collaboration between AC Immune and Life Molecular Imaging.

Nuvation Bio Announces Appointment of Colleen Sjogren as Chief Commercial Officer

Retrieved on: 
Thursday, March 28, 2024
Biotechnology, General Health, Health, Pharmaceutical, Oncology, NUVB, Janssen Pharmaceuticals, Mirati Therapeutics, Event, Medivation, Patient, Bryant University, Cancer, Senior, Kite Pharma, Sjögren, Marketing, Pharmaceutical industry

Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced the appointment of Colleen Sjogren as Chief Commercial Officer.

Key Points: 
  • Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced the appointment of Colleen Sjogren as Chief Commercial Officer.
  • Ms. Sjogren will lead the Company’s commercial strategy and operations, including marketing, sales, and market access.
  • “We are thrilled to welcome Colleen as Nuvation Bio’s first Chief Commercial Officer.
  • Of note, Colleen was one of my commercial superstars at Medivation when we launched XTANDI®,” said David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio.

Cornerstone AI Taps Viraj Narayanan as Co-CEO to Drive Industry-wide Adoption of Clean Data in Healthcare and Pharmaceuticals

Retrieved on: 
Thursday, April 4, 2024
MCK, Janssen Pharmaceuticals, Organization, Natural language processing, Growth, Narayan (name), Science, Real, Business, University, Patient, SAN, Research, Software, Senior, McKesson Corporation, MBA, Real world data, Drug development, COTA, FDA, Government, Consultant, Carnegie Mellon University, Medical device

SAN FRANCISCO, April 4, 2024 /PRNewswire-PRWeb/ -- Cornerstone AI, makers of a powerful AI software solution that cleans real world healthcare data significantly faster and more accurately than existing solutions, today announced that Viraj Narayanan has joined the company as Co-CEO. Narayanan will work alongside Cornerstone AI founder and Co-CEO Michael Elashoff to scale its highly intelligent, automated software platform which has created unparalleled efficiencies while enabling confidence in the fidelity of data needed to answer critical scientific questions.

Key Points: 
  • "Cornerstone will become the leading utility for data cleaning ," said Narayanan.
  • "Everyone is learning how AI can help organizations run more efficiently than ever before, but in healthcare, nailing the data piece is essential."
  • "We've built a remarkably robust platform to clean healthcare data at scale, without sacrificing the precision and accuracy required in life sciences," said Elashoff.
  • "Now is the time that pharmaceutical companies need to access the insights in Real World Data.

ViiV Healthcare Announces Interim Data at CROI Indicating Superior Efficacy of Long-Acting Injectable HIV Treatment Cabenuva (Cabotegravir + Rilpivirine) Compared to Daily Oral Therapy in Individuals Living With HIV Who Have Adherence Challenges

Retrieved on: 
Wednesday, March 6, 2024
Research, Infectious Diseases, Finance, Clinical Trials, Professional Services, Biotechnology, AIDS, Pharmaceutical, Health, Science, Infection, Bangladesh Technical Education Board, HIV/AIDS, RAMS, Janssen Pharmaceuticals, Failure, Aes, Rilpivirine, Fungal infection, GSK, NIAID, CROI, Research and development, Arm, ISR, Life, ACTG, Data monitoring committee, Pfizer, Johnson & Johnson, Partner (business rank), Conference, ART, History, MPH, Male, ViiV Healthcare, DSMB, Mental health, HIV, SOC, Viral load, VF, Vaccine

Kimberly Smith, MD, MPH, Head of Research & Development at ViiV Healthcare, said: “It’s estimated that one-third of people living with HIV in the United States struggle with maintaining viral suppression.

Key Points: 
  • Kimberly Smith, MD, MPH, Head of Research & Development at ViiV Healthcare, said: “It’s estimated that one-third of people living with HIV in the United States struggle with maintaining viral suppression.
  • Participants received comprehensive and incentivised adherence support while taking guideline-recommended, three-drug regimen oral ART, including dolutegravir and bictegravir-based regimens, to achieve viral suppression.
  • 24.1% of participants on LA-ART experienced regimen failure compared to 38.5% on SOC {difference -14.4 (98.75% CI–29.8%, -0.8%)}.
  • Three participants in the LA-ART arm had serious injection site reactions (ISR) and one participant discontinued due to an ISR.

New Research Study for Patients With Ulcerative Colitis Now Available in Ogden, Utah

Retrieved on: 
Tuesday, February 27, 2024
Women, Seniors, Hospitals, Men, Clinical Trials, Other Health, Biotechnology, Pharmaceutical, Consumer, Health, IBD, Ulcerative colitis, Janssen Pharmaceuticals, UC, Development, Hospital, Inflammatory bowel disease, Patient, Colitis, Nursing

Adults in the Ogden, Utah area with moderately to severely active ulcerative colitis (UC) may have the opportunity to join a research study assessing a new investigational medication.

Key Points: 
  • Adults in the Ogden, Utah area with moderately to severely active ulcerative colitis (UC) may have the opportunity to join a research study assessing a new investigational medication.
  • There is no known cure for UC, though new therapies have become available in recent years that offer patients improved treatment options.
  • The ANTHEM-UC study from Janssen Research & Development seeks to assess if an investigational pill could help those patients whose UC is not adequately managed by currently available therapies.
  • The study is now enrolling for adults age 18 or older with moderately to severely active UC, who have not responded well to currently available therapies.

Atomic AI Announces Appointments of New Independent Member to its Board of Directors and Additions to the Scientific Advisory Board

Retrieved on: 
Thursday, February 22, 2024
Research, Other Health, General Health, Pharmaceutical, Infectious Diseases, Hospitals, Clinical Trials, Science, Cardiology, Biotechnology, FDA, Health, Other Science, Molecule, Organic chemistry, Viral, Senior, Janssen Pharmaceuticals, Dartmouth College, SAB, Neuroscience, Beclabuvir, PTC Therapeutics, University, RNA, Jan Vansina, RSV, HIV-1, Atomic, Johnson & Johnson, Stroke, Bristol Myers Squibb, MBA, BMS, Therapy, Journal, HCV, PTC, Drug discovery, Meanwell, McArdle Laboratory, American Academy, Royal Society, Daclatasvir, Harvard University, Asunaprevir, Doctor of Philosophy, Thrombosis, Rutgers University, Patient, Outline of physical science, American Chemical Society, Deep learning, Publication, Cancer, Medicinal chemistry, Pharmaceutical industry

Atomic AI, a biotechnology company fusing cutting-edge machine learning with state-of-the-art structural biology to unlock RNA drug discovery, today announced the appointment of Stuart Peltz, Ph.D. as an independent board member to the Atomic AI Board of Directors, and the additions of Percy Carter, MBA, Ph.D., and Nicholas Meanwell, Ph.D. to their Scientific Advisory Board (SAB).

Key Points: 
  • Atomic AI, a biotechnology company fusing cutting-edge machine learning with state-of-the-art structural biology to unlock RNA drug discovery, today announced the appointment of Stuart Peltz, Ph.D. as an independent board member to the Atomic AI Board of Directors, and the additions of Percy Carter, MBA, Ph.D., and Nicholas Meanwell, Ph.D. to their Scientific Advisory Board (SAB).
  • “We are extremely pleased to have these highly regarded, experienced biotech leaders join in our efforts and believe in our mission,” said Raphael Townshend, Ph.D., Founder and CEO of Atomic AI.
  • Peltz’s experience will help shape our strategy as we endeavor to streamline the discovery and development of novel therapies.
  • “They have demonstrated tremendous progress integrating deep learning foundation models with experimental results to be able to predict and optimize RNA structures to enable rational drug design.

Foundational V3 Framework Extended to Incorporate Usability Validation of Sensor-Based Digital Health Technologies

Retrieved on: 
Tuesday, February 27, 2024
Digital health, EMA, Algorithm, Informatics, NIH, FDA, Drug development, Regeneron Pharmaceuticals, Johnson & Johnson, Janssen Pharmaceuticals, Manuscript, Actigraphy, TNO, Patient, Crash course, Dime, Trust, Verification, Public, Medical device

BOSTON, Feb. 27, 2024 /PRNewswire/ -- To support the rapid evolution of digital clinical measures, today, the Digital Health Measurement Collaborative Community (DATAcc) by the Digital Medicine Society (DiMe) released an extension of its foundational Verification, Analytical Validation, and Clinical Validation (V3). The V3+ extension adds a fourth component of "Usability Validation," incorporating the evaluation of user experience at scale. Additional resources, a supporting manuscript, and new educational material are now available to make it easy for developers to implement it as they build sensor-based digital health technologies (sDHTs).

Key Points: 
  • BOSTON, Feb. 27, 2024 /PRNewswire/ -- To support the rapid evolution of digital clinical measures, today, the Digital Health Measurement Collaborative Community ( DATAcc ) by the Digital Medicine Society ( DiMe ) released an extension of its foundational Verification, Analytical Validation, and Clinical Validation (V3).
  • The V3+ extension adds a fourth component of "Usability Validation," incorporating the evaluation of user experience at scale.
  • The three components of the original V3 framework remain unchanged; the V3+ framework is now extended to evaluate the ease of use, efficiency, and user satisfaction of sDHTs.
  • "I was proud to join DATAcc in the development of V3+ to include usability as a requirement in this framework.

MeiraGTx Announces $50 Million Milestone from Janssen Pharmaceuticals

Retrieved on: 
Tuesday, February 13, 2024
Technology transfer, J&J, Johnson & Johnson, Janssen Pharmaceuticals

“We are very happy to announce that the LUMEOS extension study has been initiated, which triggered the $50 million milestone payment to MeiraGTx under the asset purchase agreement with J&J,” said Alexandria Forbes, Ph.D., president and chief executive officer of MeiraGTx.

Key Points: 
  • “We are very happy to announce that the LUMEOS extension study has been initiated, which triggered the $50 million milestone payment to MeiraGTx under the asset purchase agreement with J&J,” said Alexandria Forbes, Ph.D., president and chief executive officer of MeiraGTx.
  • MeiraGTx anticipates receiving an additional $15 million in near-term milestone payments later in 2024.
  • The Company will receive up to a further $285 million upon first commercial sales of bota-vec in the U.S. and EU and for manufacturing technology transfer.
  • MeiraGTx also entered into a commercial supply agreement with J&J for bota-vec manufacturing, which the Company anticipates will generate additional revenue during the product launch.